Patent ID: 7708992

Claim:
A method for producing an antibody composition with increased antibody-dependent cellular cytotoxicity, comprising: (a) providing an isolated animal host cell comprising a first α-1,6-fucosyltransferase activity; (b) modifying said host cell, said modification being by selection in the presence of lectins, or genetic modification, so as to reduce or eliminate the first α-1,6-fucosyltransferase activity to produce a modified host cell having a second α-1,6-fucosyltransferase activity or no α-1,6-fucosyltransferase activity, said second α-1,6-fucosyltransferase activity being less than said first α-1,6-fucosyltransferase activity; (c) introducing a nucleic acid sequence encoding an IgG antibody, in expressible form, into the modified host cell, wherein said host cell expresses said nucleic acid sequence; (d) producing an IgG antibody composition comprising a mixture of IgG antibodies, said mixture comprising IgG antibodies wherein at least one of the N-acetylglucosamine residues of the reducing terminal of an N-glycoside-linked sugar chain bound to the Fc region of the IgG antibody does not contain an α-1,6-linked fucose and said IgG antibody composition has an enhanced antibody-dependent cellular cytotoxicity activity as compared to an IgG antibody composition produced in said host cell having said first α-1,6- fucosyltransferase activity.